Top Decliner: Audentes Therapeutics, Inc. (BOLD)

The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the BOLD is 1.30%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments.

Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that BOLD. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public. The insider transactions of the company (6-month change in insider ownerships) for the Audentes Therapeutics, Inc. (NASDAQ:BOLD) is -12.87%.

Institutional transactions is the amount of a Audentes Therapeutics, Inc. (NASDAQ:BOLD)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the BOLD is 1.49%.
[finviz ticker=BOLD]
A Healthcare sector firm, Audentes Therapeutics, Inc. (NASDAQ:BOLD) stock went down -6.65% on Sunday and when day-trade ended the stock finally concluded at $36.22 and number of shares that changed hands during the day are 350367. The number of shares BOLD stock currently held by all its shareholders are 43.53 and floated shares, the number of shares are available for trading in an open market on last trading day are 40.65. The average volume of shares for 3 months is 580.05 and BOLD stock value has moved between $17.93 – 42.61 in last one year.

The Audentes Therapeutics, Inc. (NASDAQ:BOLD)’s latest earnings date is 8/6/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. Audentes Therapeutics, Inc. (NASDAQ:BOLD) stock has gained 69.89% in 2019 to date.

Audentes Therapeutics, Inc. (NASDAQ:BOLD)’s monthly stock performance is -2.92%, the quarterly performance is -6.87%, the half year performance is calculated as 64.56%. The yearly performance of BOLD is -9.31%.

The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Audentes Therapeutics, Inc. (NASDAQ:BOLD) weekly volatility is measured as 3.92% and monthly volatility measured as 4.54%.

Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. BOLD return on assets is -37.40%, the return on equity (ROE) of the Audentes Therapeutics, Inc. (NASDAQ:BOLD) is -40.80%.

The price to book ratio is 3.93, price to cash per share ration is 4.27.

Analysts mean target price for Audentes Therapeutics, Inc. (NASDAQ:BOLD) is $44.80 while analysts mean recommendation is 2.20. The current share price indicates that stock is -15.17% away from its one year high and is moving 101.78% ahead of its 52-week low. BOLD’s distance from 20 day simple moving average is -5.63% and distance from 50-Day simple moving average is -5.00%.

See also  Don’t Miss: Xenetic Biosciences, Inc. (NASDAQ:XBIO)

Leave a Reply